Gina Tomaine

Conference Coverage

Weekend Infusion Model Reduces Emergency Department Visits and Length of Stay for Oncology Patients

11/14/2024

The expansion of infusion services to a weekend-inclusive model led to less emergency department visits, saved inpatient days, and reduced hospital length of stay for oncology patients, according to data presented at the 2024 JADPRO meeting.

The expansion of infusion...

11/14/2024

APP Institute Oncology

News

Posttransplant Cyclophosphamide Plus Cyclosporine A Effectively Prevents Severe GVHD: HOVON-96 Trial

07/18/2022

Gina Tomaine ;

Study findings suggest posttransplant cyclophosphamide effectively prevents severe GVHD and could allow for implementation of early posttransplant chemotherapy and immunotherapy to further reduce risk of relapse after alloHSCT.

Study findings suggest...

07/18/2022

Oncology

Conference Coverage

Tolerability and Efficacy of Azacitidine Plus Venetoclax Maintenance for Patients With AML

12/11/2022

Gina Tomaine ;

Low-dose azacitidine plus venetoclax demonstrates tolerability and feasibility as maintenance therapy for patients with AML, according to findings from a phase 2 trial with over 13 months of follow-up.

Low-dose azacitidine plus...

12/11/2022

Oncology

News

Mezigdomide and Dexamethasone Combination Demonstrates Promising Efficacy for Patients With R/R Multiple Myeloma

09/29/2023

Gina Tomaine ;

Oral mezigdomide combined with dexamethasone demonstrated promising efficacy among patients with heavily pretreated, relapsed/refractory multiple myeloma, according to a phase 1/2 study.

Oral mezigdomide combined with...

09/29/2023

Oncology

News

Second-Line Lisocabtagene Maraleucel vs Standard of Care for Relapsed/Refractory LBCL: TRANSFORM Trial

08/23/2022

Gina Tomaine ;

An interim analysis of the phase 3 TRANSFORM trial has shown significantly improved EFS with second-line lisocabtagene maraleucel vs standard of care salvage immunochemotherapy followed by autologous stem cell transplantation in relapsed or...

An interim analysis of the phase...

08/23/2022

Oncology

News

FDA Grants Expedited Approval to Omidubicel for Patients With Hematologic Malignancies

04/18/2023

Gina Tomaine ;

The FDA granted approval to omidubicel-onlv treatment for patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning.

The FDA granted approval to...

04/18/2023

Oncology

News

Lenalidomide Plus Rituximab vs Rituximab and Chemotherapy for Untreated Follicular Lymphoma

09/01/2022

Gina Tomaine ;

Lenalidomide plus rituximab provides an acceptable alternative to rituximab plus chemotherapy for patients with untreated advanced follicular lymphoma, according to long-term results from the RELEVANCE trial.

Lenalidomide plus rituximab...

09/01/2022

Oncology

News

Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera

05/05/2023

Gina Tomaine ;

Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.

Ruxolitinib therapy was found to...

05/05/2023

Oncology

News

Real-World Treatment Patterns and Outcomes in Newly Diagnosed MCL

08/02/2022

Gina Tomaine ;

Findings from a retrospective study show 1 in 4 young patients with MCL received first-line cytarabine followed by autoHSCT in the real-world setting, suggesting a need for novel treatments in routine clinical practice.

Findings from a retrospective...

08/02/2022

Oncology

Conference Coverage

Venetoclax Plus Azacitidine Sustains OS Benefit for Patients With AML Ineligible for Intensive Chemotherapy

12/11/2022

Gina Tomaine ;

Long-term follow-up results from the phase 3 VIALE-A trial show sustained OS benefit with venetoclax plus azacitidine vs placebo plus azacitidine for patients with AML ineligible for intensive chemotherapy.

Long-term follow-up results from...

12/11/2022

Oncology